Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
November 16 2020 - 9:15AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
Notification
of Late Filing
SEC
File Number: 1-16467
CUSIP
Number: 761227206
(Check
one):
[ ]
Form 10-K
|
[ ]
Form 20-F
|
[ ]
Form 11-K
|
[X]
Form 10-Q
|
[ ]
Form 10-D
|
[ ]
Form N-CEN
|
[ ]
Form N-CSR
|
|
For
Period Ended: September 30, 2020
[ ]
Transition Report on Form 10-K
|
[ ]
Transition Report on Form 20-F
|
[ ]
Transition Report on Form 11-K
|
[ ]
Transition Report on Form 10-Q
|
For
the Transition Period Ended:
Nothing
in this form shall be construed to imply that the
Commission
has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not
applicable.
PART
I - REGISTRANT INFORMATION
RESPIRERX
PHARMACEUTICALS INC.
Full
Name of Registrant
126
Valley Road, Suite C
Address
of Principal Executive Office (Street and Number)
Glen
Rock, New Jersey 07452
(City,
State and Zip Code)
PART
II - RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate) [X]
(a)
|
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed due date; and
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III - NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
RespireRx
Pharmaceuticals Inc. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Quarterly
Report on Form 10-Q for the period ended September 30, 2020 (the “Quarterly Report”) by the November 16, 2020 filing
date applicable to smaller reporting companies due to additional time needed for the Board of Directors (acting as the Audit Committee)
of the Registrant to complete its review of the Quarterly Report with the Registrant’s independent registered accounting
firm. This delay was also a result of the current public health crisis and related disruptions in working arrangements of parties
necessary to the coordination of the process. As a result, the Registrant is still in the process of preparing disclosure and
accumulating validating information needed to complete the Quarterly Report and requires additional time for its completion. The
Registrant intends to file a complete Quarterly Report as soon as practicable within the extension period of five calendar days
provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.
PART
IV - OTHER INFORMATION
Name
and telephone number of person to contact in regard to this notification:
Jeff
E. Margolis
|
(201)
|
444-4947
|
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s).
[X]
Yes [ ] No
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will
be reflected by the earnings statements to be included in the subject report or portion thereof?
[ ]
Yes [X] No
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
RespireRx
Pharmaceuticals Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
November 16, 2020
|
RespireRx
Pharmaceuticals Inc.
|
|
|
|
|
By:
|
/s/
Jeff E. Margolis
|
|
|
Jeff
E. Margolis
|
|
|
Senior
Vice President, Chief Financial Officer,
Treasurer
and Secretary
|
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jul 2024 to Aug 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Aug 2023 to Aug 2024